[Auto-immune liver diseases and their treatment]

Area of Science:

• Hepatology
• Immunology
• Gastroenterology

Context:

• Autoimmune liver diseases encompass autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC).
• Effective management strategies are crucial for improving patient outcomes and preventing disease progression.

Purpose:

• To outline current therapeutic approaches for major autoimmune liver diseases.
• To highlight the efficacy of specific treatments in managing disease activity and progression.

Summary:

• For autoimmune hepatitis, prednisone, potentially with azathioprine, can enhance quality of life and prevent cirrhosis. Alternative therapies include mycophenolate mofetil or cyclosporin if initial treatment fails or is not tolerated.
• Ursodeoxycholic acid (UDCA) is effective in slowing fibrosis progression in primary biliary cirrhosis at dosages of 13-15 mg/kg/day. Higher UDCA doses (20-30 mg/kg/day) also slow fibrosis.
• Symptomatic treatment for pruritus in PBC may involve cholestyramine, rifampicin, or opiate antagonists.

Impact:

• Provides a concise overview of treatment options for common autoimmune liver conditions.
• Informs clinical decision-making for managing autoimmune hepatitis and primary biliary cirrhosis.
• Emphasizes the role of pharmacotherapy in disease modification and symptom management.